AN ACT to amend Tennessee Code Annotated, Title 4; Title 38, Chapter 3; Title 39, Chapter 17; Title 43; Title 50; Title 53; Title 63; Title 67 and Title 68, relative to the "Tennessee Medical Cannabis Act."
SB0489 creates the “Tennessee Medical Cannabis Act,” establishing a comprehensive state framework to authorize and regulate medical cannabis for patients with qualifying medical conditions. The bill sets up a patient and caregiver card system, defines qualifying conditions, and requires medical certification from licensed healthcare providers. It also creates a new Tennessee medical cannabis program commission to administer the program, issue rules, oversee licensing, maintain registries, and coordinate enforcement with the Department of Agriculture.
The bill authorizes a regulated supply chain for medical cannabis from cultivation through sale, including licenses for cultivation, processing, transportation, testing, manufacturing, and dispensaries. It requires track-and-trace systems, product testing, packaging and labeling standards, security requirements, background checks, and confidentiality protections for patient data. The bill also limits use during pregnancy, restricts employer and insurer obligations, and preempts conflicting criminal and civil laws for activity conducted in compliance with the act.
The bill would substantially amend Tennessee law by carving out a state-regulated medical cannabis program from existing controlled-substance and related criminal provisions, including making compliant medical cannabis activity exempt from specified drug offenses. It adds a new part to Title 68 and also amends Title 4 to create the commission as a state entity. The measure would shift regulatory authority to the new commission and the Department of Agriculture, establish licensing and inspection regimes, create a medical cannabis fund, impose state and local taxes on medical cannabis sales, and allocate portions of tax revenue to agriculture, rural development, veterans PTSD programs, and law enforcement training.
The bill’s structure and findings suggest a strongly supportive posture toward medical cannabis, emphasizing patient access, public health, opioid-overdose reduction, agricultural development, and research. The absence of committee transcripts and recorded votes means there is no direct evidence in the provided materials of opposition or support from specific members, but the bill text itself reflects a detailed, affirmative effort to implement a tightly controlled program rather than a permissive one. Overall, the measure appears designed to reassure regulators and the public through extensive oversight, testing, and enforcement provisions.
The main points of potential contention are the scope and design of the program: the bill creates a new commission, sets significant licensing fees, limits the number of initial licenses, and gives the state broad control over who may participate in the market. Other likely areas of debate include the breadth of qualifying conditions, the exclusion of smoking and vaping from medical cannabis-infused products, the local option allowing counties and municipalities to ban operations by supermajority vote, and the tax structure. Business access and market concentration may also be disputed because the bill restricts ownership interests, imposes residency requirements, and tightly regulates transfers and vertical integration.